BioSpace News Archive

Predictive Oncology Inc. announced the appointment of Robert F. Murphy, Ph.D., to the company’s Scientific Advisory Board where he will serve alongside other key thought leaders in their respective fields to guide the company’s scientific initiatives and growth strategy.

VolitionRx Limited announces the availability of its Nu.Q® Vet Cancer Test through the IDEXX Laboratories, Inc. reference laboratory network in the U.S.

The American Academy of Pediatrics (AAP), the Pediatric Endocrine Society (PES) and the American Thyroid Association (ATA) have published new guidelines for the treatment of congenital hypothyroidism (CH).

Looking to harness the potential of non-invasive ultrasound technology, clinicians at Northwell Health and clinical trial investigators at The Feinstein Institutes for Medical Research have begun to participate in the Alpheus™ Medical, Inc phase 1 clinical trial and enrolled its first set of patients at North Shore University Hospital (NSUH).

American Cancer Society’s (ACS) Cancer Facts & Figures 2023 report, released today, shows that the five-year survival rate for pancreatic cancer has reached a new all-time high of 12%, an increase of one percentage point from last year.

Pluristyx and panCELLa today are excited to announce the granting of a patent used in their universal, off-the-shelf, induced pluripotent stem cells (iPSCs).

Harbour BioMed (the"Company”, HKEX: 02142) announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to commence clinical trials of its globally first-in-class fully human monoclonal antibody HBM1020 targeting B7H7 (also known as HHLA2) in the U.S.

Paxlovid (nirmatrelvir with ritonavir) has been shown in clinical studies to be a highly-effective treatment to mitigate the severity of a COVID-19 infection—with some studies showing it can be close to 90% effective in reducing the risk of severe disease, and in reducing hospitalization for people age 65 and over.

Terns Pharmaceuticals, Inc. today announced that management will participate in a fireside chat at the B. Riley Securities 3rd Annual Oncology Conference on Wednesday, January 18, 2023 at 2:30 p.m.

MediciNova, Inc. announced that the Phase 2 clinical trial evaluating MN-166 in recurrent and newly diagnosed glioblastoma conducted at Dana-Farber Cancer Institute has completed enrollment.